How have you been incorporating Abemaciclib into the adjuvant management of high risk node positive HR+ breast cancer?
Given arguments exist between the FDA and ASCO, where do you stand?
Answer from: Medical Oncologist at Academic Institution
To date, I have used local lab results for Ki-67 and had no issues with insurance coverage. Our breast team has otherwise been attempting to utilize abemacicilib in situations that meet the monarch-E protocol (Patients with four or more positive nodes, or one to three nodes and either tumor size &ge...
Sign in or Register to read more